Get the Stockscreener App
1.06
10.17%
-0.12
Alx Oncology Holdings Inc stock is traded at $1.06, with a volume of 410.05K.
It is down -10.17% in the last 24 hours and up +72.33% over the past month.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.
See More
Previous Close:
$1.18
Open:
$1.18
24h Volume:
410.05K
Relative Volume:
0.46
Market Cap:
$56.76M
Revenue:
-
Net Income/Loss:
$-151.16M
P/E Ratio:
-0.3569
EPS:
-2.97
Net Cash Flow:
$-130.08M
1W Performance:
-13.11%
1M Performance:
+72.33%
6M Performance:
+10.49%
1Y Performance:
-50.47%
1-Day Range:
$1.01
$1.18
1-Week Range:
$1.01
$1.27
52-Week Range:
$0.404
$2.36
Alx Oncology Holdings Inc Stock (ALXO) Company Profile
Name
Alx Oncology Holdings Inc
Sector
Industry
Phone
650-466-7125
Address
323 ALLERTON AVENUE, SOUTH SAN FRANCISCO
Compare ALXO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALXO
Alx Oncology Holdings Inc
|
1.06 | 62.65M | 0 | -151.16M | -130.08M | -2.97 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Alx Oncology Holdings Inc Stock (ALXO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-06-25 | Upgrade | Jefferies | Hold → Buy |
| Dec-19-24 | Downgrade | Jefferies | Buy → Hold |
| Mar-08-24 | Downgrade | Stifel | Buy → Hold |
| Dec-08-23 | Upgrade | Jefferies | Hold → Buy |
| Dec-22-21 | Downgrade | Jefferies | Buy → Hold |
| Sep-30-21 | Initiated | Stifel | Buy |
| May-05-21 | Resumed | Credit Suisse | Outperform |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Apr-06-21 | Initiated | UBS | Buy |
| Feb-10-21 | Initiated | H.C. Wainwright | Buy |
| Aug-11-20 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-11-20 | Initiated | Credit Suisse | Outperform |
| Aug-11-20 | Initiated | Jefferies | Buy |
| Aug-11-20 | Initiated | Piper Sandler | Overweight |
View All
Alx Oncology Holdings Inc Stock (ALXO) Latest News
How to escape a deep drawdown in ALX Oncology Holdings Inc.Weekly Trade Review & AI Driven Price Predictions - Newser
Full technical analysis of ALX Oncology Holdings Inc. stockMarket Sentiment Summary & AI Forecast for Swing Trade Picks - Newser
ALX Oncology Holdings Inc. stock outlook for YEARMarket Activity Report & Technical Pattern Based Signals - Newser
Applying Elliott Wave Theory to ALX Oncology Holdings Inc.July 2025 Institutional & Safe Investment Capital Preservation Plans - Newser
Using Python tools to backtest ALX Oncology Holdings Inc. strategiesDividend Hike & Intraday High Probability Alerts - Newser
Using AI based signals to follow ALX Oncology Holdings Inc.Weekly Stock Summary & Verified Entry Point Signals - Newser
ALX Oncology Announces Management Changes Amidst Nasdaq Compliance - TipRanks
Will breakout in ALX Oncology Holdings Inc. lead to full recovery2025 Performance Recap & Entry Point Strategy Guides - Newser
ALX Oncology appoints board member Klencke as interim CMO - Investing.com
Does ALX Oncology Holdings Inc. show high probability of rebound2025 Breakouts & Breakdowns & Consistent Income Trade Ideas - Newser
Long term hold vs stop loss in ALX Oncology Holdings Inc.Gap Down & Advanced Swing Trade Entry Alerts - Newser
Using economic indicators to assess ALX Oncology Holdings Inc. potentialMarket Weekly Review & AI Powered Market Entry Ideas - Newser
ALX Oncology Appoints Dr. Barbara Klencke as Interim Chief Medical Officer Following Departure of Dr. Alan Sandler - Quiver Quantitative
ALX Oncology Appoints Board Member Barbara Klencke, M.D., as Interim Chief Medical Officer - GlobeNewswire
30-Year Oncology Veteran Dr. Barbara Klencke Takes Helm as ALX Oncology's New Interim CMO - Stock Titan
How to forecast ALX Oncology Holdings Inc. trends using time series2025 Sector Review & Accurate Entry/Exit Alerts - Newser
Is ALX Oncology Holdings Inc. trending in predictive chart modelsEarnings Recap Summary & Real-Time Volume Analysis Alerts - Newser
Published on: 2025-09-12 04:00:45 - Newser
Does ALX Oncology Holdings Inc. fit your quant trading modelWeekly Market Summary & Weekly High Potential Stock Alerts - Newser
Sector ETF performance correlation with ALX Oncology Holdings Inc.2025 Dividend Review & Technical Buy Zone Confirmation - Newser
What the charts say about ALX Oncology Holdings Inc. todayWeekly Investment Recap & Verified Stock Trade Ideas - Newser
Strategies to average down on ALX Oncology Holdings Inc.Rate Hike & High Return Stock Watch Alerts - Newser
Published on: 2025-09-11 19:28:20 - Newser
Is ALX Oncology Holdings Inc. meeting your algorithmic filter criteriaJuly 2025 News Drivers & AI Forecast Swing Trade Picks - Newser
Trend analysis for ALX Oncology Holdings Inc. this weekJuly 2025 Earnings & Long-Term Safe Return Strategies - Newser
What MACD and RSI say about ALX Oncology Holdings Inc.2025 Trading Volume Trends & Fast Moving Trade Plans - Newser
Tick level data insight on ALX Oncology Holdings Inc. volatility2025 Support & Resistance & Stock Market Timing Techniques - Newser
ALX Oncology Holdings Inc. stock daily chart insights2025 Earnings Impact & AI Enhanced Trading Signals - Newser
using python tools to backtest alx oncology holdings inc. strategies2025 Pullback Review & Risk Controlled Daily Plans - Newser
ALX Oncology Doses First Patient in Phase 1 Dose Escalation Trial Evaluating ADC ALX2004 for the Treatment of EGFR-Expressing Solid Tumors - Investing News Network
ALX Oncology Holdings Inc. stock trend outlook and recovery pathJuly 2025 Setups & Weekly Breakout Stock Alerts - Newser
Is ALX Oncology Holdings Inc. stock reversal real or fakeMarket Growth Report & Community Verified Trade Alerts - Newser
What indicators show strength in ALX Oncology Holdings Inc.July 2025 Review & Real-Time Market Sentiment Alerts - Newser
ALX Oncology Holdings Inc. recovery potential after sell offJuly 2025 Trends & Community Consensus Picks - Newser
Tools to monitor ALX Oncology Holdings Inc. recovery probabilityJuly 2025 Fed Impact & Expert Approved Momentum Trade Ideas - Newser
ALX Oncology to Participate in Upcoming Investor Conferences in September - Investing News Network
FDA Accelerates Cancer Drug Pipeline as Market Momentum Surges Past $400B - Baystreet.ca
Analyzing net buyer seller activity in ALX Oncology Holdings Inc.Portfolio Risk Report & Safe Entry Trade Signal Reports - Newser
Alx Oncology Holdings Inc Stock (ALXO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):